<DOC>
	<DOCNO>NCT01526603</DOCNO>
	<brief_summary>This standard care document , outline therapy child high risk neuroblastoma eligible Children 's Oncology Group ( COG ) study .</brief_summary>
	<brief_title>High Dose Chemotherapy Autologous Transplant Neuroblastoma</brief_title>
	<detailed_description>This therapy involve use melphalan , etoposide , carboplatin ( consolidation chemotherapy ) ; autologous stem cell rescue , post-transplant radiation therapy maintenance phase Isotretinoin ( Accutane , 13-cis-retinoic acid ) therapy . If available , patient also consider post-transplant therapy cytokine monoclonal antibody ( ch14.18 ) COG New Approaches Neuroblastoma Therapy ( NANT ) trial .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Less 30 year age diagnosis neuroblastoma No evidence disease progression : defined increase tumor size &gt; 25 % new lesion Recovery last induction course chemotherapy ( absolute neutrophil count &gt; 500 platelet &gt; 20,000 ) No uncontrolled infection Minimum frozen peripheral blood stem cell ( PBSCs ) 2 x 10^6 CD34 cells/kg transplant mandatory 2 x 10^6 CD34 cells/kg backup strongly recommend ( thus , PBSC 4 x 106 CD34 cells/kg encourage ) Adequate organ function define : Hepatic : aspartate aminotransferase ( AST ) &lt; 3 x upper limit institutional normal 8 Cardiac : shorten fraction ≥ 27 % ejection fraction ≥ 50 % , clinical congestive heart failure 8 Renal : Creatinine clearance glomerular filtration rate ( GFR ) &gt; 60 mL/min/1.73m^2 If creatinine clearance perform end induction result &lt; 100 ml/min/1.73m^2 , GFR must perform use nuclear blood sample method iothalamate clearance method . Camera method NOT allow measure GFR prior Consolidation therapy patient GFR creatinine clearance &lt; 100 ml/min/1.73m^2 Exclusion Criteria Patients progressive disease consider participate phase I study since consolidation therapy use regimen outline document determine useful . Patients delayed consolidation chemotherapy beyond 8 week , n't meet organ function criterion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>peripheral blood stem cell transplantation</keyword>
	<keyword>autologous stem cell transplant</keyword>
</DOC>